Vol 11, No 2 (2017)
Review paper
Published online: 2017-10-12

open access

Page views 898
Article views/downloads 13056
Get Citation

Connect on Social Media

Connect on Social Media

Mechanisms of opioid analgesics addiction

Ryszard Przewłocki1
Medycyna Paliatywna w Praktyce 2017;11(2):55-60.

Abstract

Opioid addiction (opioid use disorder) is a chronic, relapsing disease of brain. Opioids induced persisting changes at the cellular and molecular levels resulted in dysregulation and remodeling of the reward system. These changes depend on genetic and environmental factors. Therapy of opioid addiction is limited and require both pharmacological therapy and psychotherapy. Understanding the neurobiological mechanisms of opioid addiction is essential for a better treatment of this disease.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 2001; 24(2): 97–129.
  2. Lüscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron. 2011; 69(4): 650–663.
  3. Volkow ND, Koob GF, McLellan AT. Neurobiologic Advances from the Brain Disease Model of Addiction. N Engl J Med. 2016; 374(4): 363–371.
  4. Kieffer BL, Gavériaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol. 2002; 66(5): 285–306.
  5. Przewlocki R. Opioid peptides. in D.W. Pfaff, N.D. Volkow (eds.), Neuroscience in the 21st Century. Springer Science+Business Media New York, 2016.
  6. Kreek MJ, Levran O, Reed B, et al. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest. 2012; 122(10): 3387–3393.
  7. Pasternak GW. Opioids and their receptors: Are we there yet? Neuropharmacology. 2014; 76 Pt B: 198–203.
  8. Kenny PJ. Epigenetics, microRNA, and addiction. Dialogues Clin Neurosci. 2014; 16(3): 335–344.
  9. DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013; 344(3): 708–717.
  10. Spahn V, Del Vecchio G, Labuz D, et al. A nontoxic pain killer designed by modeling of pathological receptor conformations. Science. 2017; 355(6328): 966–969.
  11. Manglik A, Lin H, Aryal DK, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016; 537(7619): 185–190.